Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain ...

2025 Financial Guidance Sight Sciences raises revenue guidance expectations for full year 2025 to $72.0 million to $76.0 million, representing a 5% to 10% decline compared to full year 2024 revenue, ...

Beginning in Q3 2026, the TTM revenue covenant will be $115 million and will remain at that level for all subsequent quarters through the maturity of the debt. In consideration for this fifth ...

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today an ...

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today ...

China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access Cash resources of $333.4 million as of June 30, 2025 (compared to $324.2 ...

Gross profit for the second quarter of 2025 was $25.2 million or 74.9% of revenue, an increase of $0.9 million compared to gross profit of $24.3 million or 69.5% of revenue for the second quarter of ...

BELTSVILLE, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and ...

Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported ...

LONG BEACH, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results ...

General and Administrative (G&A) Expenses. G&A expenses were $11.9 million for the three months ended June 30, 2025, compared to $8.6 million for the three months ended June 30, 2024. The increase in ...

Research and Development (R&D) expenses: R&D expenses were $22.3 million for the second quarter of 2025, compared to $27.8 million for the second quarter of 2024. General and Administrative (G&A) ...